Plasma quetiapine in relation to prescribed dose and other factors: Data from a therapeutic drug monitoring service, 2000–2011

Therapeutic Advances in Psychopharmacology

Volumn 3, Issue 3, 2013, Pages 129-137

  Handley, Simon A ^a   Bowskill, Sally V j ^a   Patel, Maxine X ^b   Flanagan, Robert J ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

adherence; quetiapine; schizophrenia; therapeutic drug monitoring

Indexed keywords

DOPAMINE 2 RECEPTOR; QUETIAPINE;

ADOLESCENT; ADULT; AGED; ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MONITORING; DRUG PROTEIN BINDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SMOKING;

EID: 84997891788     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125312470677     Document Type: Article

References (29)

1. Aichhorn W. Marksteiner J. Walch T. Zernig G. Saria A. Kemmler G. (2006) Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 21: 81–85.
2. Andersson M. Björkhem-Bergman L. Lindh J. (2011) Possible drug–drug interaction between quetiapine and lamotrigine - evidence from a Swedish TDM database. Br J Clin Pharmacol 72: 153–156.
3. Arvanitis L. Miller G. (1997) Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42: 233–246.
4. Bakken G. Rudberg I. Molden E. Refsum H. Hermann M. (2011) Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit 33: 222–226.
5. Baumann P. Hiemke C. Ulrich S. Eckermann G. Gaertner I. Gerlach M. et al. (2004) The AGNP-TDM Expert Group Consensus Guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37: 243–265.
6. BNF (2012) British National Formulary, 63rd edition. London: BMJ Group/Pharmaceutical Press.
7. Castberg I. Skogvoll E. Spigset O. (2007) Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatr 68: 1540–1545.
8. Citrome L. Jaffe A. Levine J. Lindenmayer J. (2005) Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. J Clin Psychiatry 66: 1512–1516.
9. DeVane C. Nemeroff C. (2001) Clinical pharmacokinetics of quetiapine, an atypical antipsychotic. Clin Pharmacokinet 40: 509–522.
10. El-Khalili N. Joyce M. Atkinson S. Buynak R. Datto C. Lindgren P. et al. (2010) Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 13: 917–932.
11. FDA/CDER (2001) Guidance for industry. Bioanalytical method validation. Food and Drug Administration/Center for Drug Evaluation and Research. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
12. Fisher D. Handley S. Flangan R. Taylor D. (2012a) Plasma concentrations of quetiapine, N-desalkylquetiapine, O-desalkylquetiapine, 7-hydroxyquetiapine and quetiapine sulfoxide in relation to dose, formulation and other factors. Ther Drug Monit 34: 415–421.
13. Fisher D. Handley S. Taylor D. Flanagan R. (2012b) Measurement of quetiapine and four quetiapine metabolites in human plasma by LC-MS/MS. Biomed Chromatogr 26: 1125–1132.
14. Gerlach M. Hünnerkopf R. Rothenhöfer S. Libal G. Burger R. Clement H. (2007) Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry 40: 72–6.
15. Hasselstr⊘m J. Linnet K. (2004) Quetiapine serum concentrations in psychiatric patients, the influence of comedication. Ther Drug Monit 26: 486–491.
16. Hiemke C. Baumann P. Bergemann N. Conca A. Dietmaier O. Egberts K. et al. (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44: 195–235.
17. Hukkanen J. Väisänen T. Lassila A. Piipari R. Anttila S. Pelkonen O. et al. (2003) Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharamcol Exp Ther 304: 745–752.
18. Hunfeld N. Westerman E. Boswijk D. de Haas J. van Putten M. Touw D. (2006) Quetiapine in overdosage: a clinical and pharmacokinetic analysis of 14 cases. Ther Drug Monit 28: 185–189.
19. Jensen N. Rodriguiz R. Caron M. Wetsel W. Rothman R. Roth B. (2008) N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-htia agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33: 2303–2312.
20. Marin J. Levine M. Ensom M. (2006) Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients? Ther Drug Monit 28: 637–642.
21. Mauri M. Volonteri L. Fiorentini A. Pirola R. Bareggi S. (2007) Two weeks’ quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother 8: 2207–13.
22. Nikisch G. Baumann P. Kießling B. Reinert M. Wiedemann G. Kehr J. (2010) Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. J Psychopharmacol 30: 496–503.
23. Reis M. Aberg-Wistedt A. Agren H. Akerblad A. Bengtsson F. (2008) Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations. J Affective Disorders 82: 443–446.
24. Sparshatt A. Jones S. Taylor D. (2008) Quetiapine, dose–response relationship in schizophrenia. CNS Drugs 22: 49–68.
25. Sparshatt A. Taylor D. Patel M. Kapur S. (2011) Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: A review. J Clin Psychiatr 72: 1108–23.
26. Spina E. de Leon J. (2007) Metabolic drug interactions with newer antipsychotics: A comparative review. Basic Clin Pharmacol Toxicol 100: 4–22.
27. Taylor D. Paton C. Kapur S. (2012) The Maudsley Prescribing Guidelines, 11th edition. London: Informa Healthcare.
28. Tholen D. Kallner A. Kennedy J. Krouwer J. Meier K. (2004) Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline – Second Edition. Available at: http://webstore.ansi.org/ansidocstore/product.asp?sku=EP05%2DA2.
29. Wittmann M. Hausner H. Köstlbacher A. Hajak G. Haen E. (2010) Individual clearance and therapeutic drug monitoring of quetiapine in clinical practice. Neuro-Endocrin Lett 31: 203–207.